CLINICAL TRIALS PROFILE FOR PRIMAXIN

All Clinical Trials for PRIMAXIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00619710 ↗	Complicated Skin and Skin Structure Infections	Completed	AstraZeneca	Phase 3	2001-02-01	The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.
NCT00619710 ↗	Complicated Skin and Skin Structure Infections	Completed	Pfizer	Phase 3	2001-02-01	The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.
NCT01275170 ↗	A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)	Completed	Merck Sharp & Dohme Corp.	Phase 1	2011-01-28	This is a 2-part study of the pharmacokinetics (PK) of MK-7655. In Part I, the PK of a single 125 mg dose of MK-7655 given in combination with 250 mg of PRIMAXIN® (imipenem + cilastatin) will be determined in participants with impaired renal function and matched control participants. In Part II, the potential for renal insufficiency to affect non-renal clearance mechanisms will be investigated.

Clinical Trial Conditions for PRIMAXIN

Condition Name

Condition Name for PRIMAXIN
Intervention	Trials
Abscess	1
Cellulitis	1
Infectious Disease	1
Skin Infection	1

Condition MeSH

Condition MeSH for PRIMAXIN
Intervention	Trials
Infections	2
Infection	2
Communicable Diseases	2
Cellulitis	1

Clinical Trial Progress for PRIMAXIN

Clinical Trial Phase

Clinical Trial Phase for PRIMAXIN
Clinical Trial Phase	Trials
Phase 3	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for PRIMAXIN
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for PRIMAXIN

Sponsor Name

Sponsor Name for PRIMAXIN
Sponsor	Trials
AstraZeneca	1
Pfizer	1
Merck Sharp & Dohme Corp.	1

Sponsor Type

Sponsor Type for PRIMAXIN
Sponsor	Trials
Industry	3